Antigen-binding domains of the monoclonal anti-collagen i antibody
AssigneeThomas Jefferson University
InventorsAndrzej FERTALA, Andrzej STEPLEWSKI
Life of this patent
Estimating the term…
Abstract
An anti-fibrotic biologic comprising, a full-length chimeric IgG variant, a humanized IgG variant, a scFv variant, or other active biologic including the entire CDRs or their fragments able to bind to the α2Ct target.
Claims36
A monoclonal antibody comprising the amino acid sequences of the complementarity determining regions (CDRs) of the heavy alpha chain corresponding to and the light kappa chain corresponding to of a monoclonal antibody (denoted as anti-fibrotic antibody, AFA) that blocks the binding activity of the C-terminal telopeptide region of human collagen I (denoted as CTTR1) consisting of two α1(I)C-telopeptides (denoted as α1Ct) and one α2(I)C-telopeptide (denoted as α2Ct).
A monoclonal antibody-based biologics in systemic or localized fibrotic diseases to limit the progression of the fibrotic process.
An anti-fibrotic biologic comprising, a full-length chimeric IgG variant, a humanized IgG variant, a scFv variant, or other active biologic including the entire CDRs or their fragments able to bind to the α2Ct target.
A pharmaceutical composition comprising an antibody having a variable chain of SEQ ID No. 2, and of SEQ ID No. 6.
A pharmaceutical composition comprising an antibody having CDR's corresponding to SEQ ID Nos. 3, 4, 5, in the heavy chain and 7, 8, and 9 in the light chain.
A method of limiting growth of fibrotic tissue by blocking collagen fibril formation comprising administering to a patient an effective amount of an anti-fibrotic antibody.
A method of delivering targeted therapeutic compounds to collagen I rich connective tissues comprising administering to a patient an effective amount of an antibody having affinity for collagen I rich tissues, and comprising a therapeutic compound bound to said antibody.
Dependencies are inferred from the claim text.